Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $61.4 million.

  • Adma Biologics' Cash & Equivalents fell 2920.41% to $61.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.4 million, marking a year-over-year decrease of 2920.41%. This contributed to the annual value of $103.1 million for FY2024, which is 10086.27% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Cash & Equivalents is $61.4 million, which was down 2920.41% from $90.3 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Cash & Equivalents ranged from a high of $103.1 million in Q4 2024 and a low of $34.4 million during Q3 2021
  • Its 5-year average for Cash & Equivalents is $65.1 million, with a median of $62.5 million in 2023.
  • In the last 5 years, Adma Biologics' Cash & Equivalents tumbled by 4233.68% in 2021 and then skyrocketed by 11257.08% in 2023.
  • Adma Biologics' Cash & Equivalents (Quarter) stood at $51.1 million in 2021, then skyrocketed by 69.36% to $86.5 million in 2022, then plummeted by 40.65% to $51.4 million in 2023, then skyrocketed by 100.86% to $103.1 million in 2024, then tumbled by 40.49% to $61.4 million in 2025.
  • Its Cash & Equivalents was $61.4 million in Q3 2025, compared to $90.3 million in Q2 2025 and $71.6 million in Q1 2025.